Measures of survival benefit in cancer drug development and their limitations

Ruth Etzioni, Roman Gulati, Daniel W. Lin

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Background: A variety of measures of survival benefit are available to an investigator comparing outcomes across the various arms of a drug development trial. In this article, we systematically review the most common measures of comparative survival used in published studies. Materials: We distinguish between relative and absolute survival differences, and measures of instantaneous and cumulative risk. We consider settings in which the end point is overall survival as well as those in which disease-specific end points are of primary interest. Results: We note that different measures capture different aspects of benefit, and some may be more reliable than others or more representative of clinically relevant benefit. Conclusions: Rather than simply using procedures that have become standard, analyses should identify the most clinically relevant measures of effect and apply procedures that reliably estimate these.

Original languageEnglish (US)
Pages (from-to)122-127
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Volume33
Issue number3
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Pharmaceutical Preparations
Neoplasms
Research Personnel

Keywords

  • Competing risks
  • Disease-specific mortality
  • Survival analysis

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Measures of survival benefit in cancer drug development and their limitations. / Etzioni, Ruth; Gulati, Roman; Lin, Daniel W.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 33, No. 3, 01.01.2015, p. 122-127.

Research output: Contribution to journalReview article

Etzioni, Ruth ; Gulati, Roman ; Lin, Daniel W. / Measures of survival benefit in cancer drug development and their limitations. In: Urologic Oncology: Seminars and Original Investigations. 2015 ; Vol. 33, No. 3. pp. 122-127.
@article{e16903ed0c444631b20fe63ac6103798,
title = "Measures of survival benefit in cancer drug development and their limitations",
abstract = "Background: A variety of measures of survival benefit are available to an investigator comparing outcomes across the various arms of a drug development trial. In this article, we systematically review the most common measures of comparative survival used in published studies. Materials: We distinguish between relative and absolute survival differences, and measures of instantaneous and cumulative risk. We consider settings in which the end point is overall survival as well as those in which disease-specific end points are of primary interest. Results: We note that different measures capture different aspects of benefit, and some may be more reliable than others or more representative of clinically relevant benefit. Conclusions: Rather than simply using procedures that have become standard, analyses should identify the most clinically relevant measures of effect and apply procedures that reliably estimate these.",
keywords = "Competing risks, Disease-specific mortality, Survival analysis",
author = "Ruth Etzioni and Roman Gulati and Lin, {Daniel W.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.urolonc.2014.11.002",
language = "English (US)",
volume = "33",
pages = "122--127",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Measures of survival benefit in cancer drug development and their limitations

AU - Etzioni, Ruth

AU - Gulati, Roman

AU - Lin, Daniel W.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: A variety of measures of survival benefit are available to an investigator comparing outcomes across the various arms of a drug development trial. In this article, we systematically review the most common measures of comparative survival used in published studies. Materials: We distinguish between relative and absolute survival differences, and measures of instantaneous and cumulative risk. We consider settings in which the end point is overall survival as well as those in which disease-specific end points are of primary interest. Results: We note that different measures capture different aspects of benefit, and some may be more reliable than others or more representative of clinically relevant benefit. Conclusions: Rather than simply using procedures that have become standard, analyses should identify the most clinically relevant measures of effect and apply procedures that reliably estimate these.

AB - Background: A variety of measures of survival benefit are available to an investigator comparing outcomes across the various arms of a drug development trial. In this article, we systematically review the most common measures of comparative survival used in published studies. Materials: We distinguish between relative and absolute survival differences, and measures of instantaneous and cumulative risk. We consider settings in which the end point is overall survival as well as those in which disease-specific end points are of primary interest. Results: We note that different measures capture different aspects of benefit, and some may be more reliable than others or more representative of clinically relevant benefit. Conclusions: Rather than simply using procedures that have become standard, analyses should identify the most clinically relevant measures of effect and apply procedures that reliably estimate these.

KW - Competing risks

KW - Disease-specific mortality

KW - Survival analysis

UR - http://www.scopus.com/inward/record.url?scp=84925338408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925338408&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2014.11.002

DO - 10.1016/j.urolonc.2014.11.002

M3 - Review article

C2 - 25813143

AN - SCOPUS:84925338408

VL - 33

SP - 122

EP - 127

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 3

ER -